tiprankstipranks
Trending News
More News >

RemeGen Co., Ltd. Releases 2025 Q1 Financial Report

Story Highlights
  • RemeGen Co., Ltd. operates in the pharmaceutical industry, focusing on innovative drugs.
  • The company released unaudited Q1 2025 financial data, advising caution to stakeholders.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
RemeGen Co., Ltd. Releases 2025 Q1 Financial Report

Confident Investing Starts Here:

RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement.

RemeGen Co., Ltd. has released its unaudited financial data for the first quarter of 2025, prepared according to Chinese accounting principles. The report has been reviewed by the company’s audit committee but not by independent auditors, and stakeholders are advised to exercise caution when dealing with the company’s securities.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, with a market presence on the Shanghai Stock Exchange and the Hong Kong Stock Exchange.

YTD Price Performance: 201.74%

Average Trading Volume: 6,991,215

Technical Sentiment Signal: Sell

Current Market Cap: HK$27.68B

See more data about 9995 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1